ONCOassist

07/04/2026

🚨 Latest 3 Trial Update!

🔷 The Phase III EMERALD-3 trial demonstrated that Imfinzi® plus Imjudo® in combination with Lenvatinib and TACE significantly improved progression-free survival in patients with embolisation-eligible unresectable liver cancer. The results highlight the potential of this multi-modal approach to enhance disease control and delay progression.

🔷 This clinically meaningful benefit supports the evolving role of immunotherapy-based combinations in earlier treatment settings for hepatocellular carcinoma. The findings reinforce the importance of integrating systemic therapy with locoregional strategies to improve patient outcomes.

🔗 Read more: https://bit.ly/ONCOnews-07-Apr-01

07/04/2026

👉️ Take the Basal Cell Carcinoma quiz now - https://bit.ly/BCCA_ONCO_IQ_FB

This peer-reviewed ONCO-IQ quiz is designed for oncology professionals—a fast, high-yield knowledge check you can complete in minutes.

✅️ Navigate treatment sequencing in locally advanced and HHI-refractory BCC
✅️ Apply trial evidence to real-world decision-making
✅️ Recognise resistance mechanisms and optimise next-line systemic strategies

06/04/2026

🚨 Latest Update!

🔷 The European Commission has approved KEYTRUDA in combination with Paclitaxel ± Bevacizumab for adults with PD-L1 (CPS ≥1) platinum-resistant recurrent ovarian carcinoma. This approval expands treatment options for patients who have received one or two prior systemic therapies.

🔷 The decision is supported by clinical evidence demonstrating meaningful benefit in a difficult-to-treat setting. The combination highlights continued progress toward improving outcomes in recurrent ovarian cancer through immunotherapy-based strategies.

🔗 Read more: https://bit.ly/ONCOnews-06_Apr-01

02/04/2026

*This post is NOT intended for the U.S. audience.*

👉Participate in the full quiz here: https://bit.ly/ESR1_ONCO_IQ_FB

🧬This week’s ONCO-IQ Challenge focuses on ESR1 mutations in breast cancer. Comment the right answer.

Explore ESR1 mutations in breast cancer and other oncology quizzes across multiple indications, now live on ONCOassist®.

Download the ONCOassist app:
📥 iOS: https://apple.co/4iuMxfS
📥 Android: https://lnkd.in/gexiDSKr
📥Webapp: https://lnkd.in/gBntSZ_b

01/04/2026

🎥 Oncology Bytes – IUCS 2025
Natalia Bednarz-Knoll, Ph.D., Assistant Professor, Division of Translational Oncology, Medical University of Gdańsk, presents research investigating metastasis-initiating circulating tumor cells in prostate cancer. The study combines advanced CTC phenotyping with imaging flow cytometry to better understand which disseminated tumor cell populations may be linked to recurrence and metastatic potential.

Watch here: https://youtu.be/rZocYYW_TNw

📊 Key findings:
- Over 2,500 CTCs were analyzed.
- EMT-like, smaller CTCs in peripheral blood were associated with a shorter time to biochemical recurrence.
- A rare EGFRhigh/ARneg CTC phenotype was linked to aggressive disease.
- In the presentation, this EGFRhigh/ARneg phenotype was associated with a shorter time to metastasis after radical prostatectomy.
- Platelet-coated epithelial CTCs correlated with high TGF-beta and disease progression.

This abstract adds important insight into the biology of prostate cancer dissemination and supports the growing role of phenotypic CTC profiling in risk stratification and future treatment guidance.

📄 Read the full abstract: https://urologycancersummit.org/iuc24411-77/
🗓️ Register for IUCS 2026: https://webplatform.planning.it/IUCS26/register

🌐 Learn more at: https://oncoassist.com/

Title of the abstract - In Search of Metastasis-Initiating Cells in Prostate Cancer🗓️ Register for IUCS 2026: https://webplatform.planning.it/IUCS26/registe...

31/03/2026

This post is not intended for the U.S. audience.

👉️ Take the ESR1 Mutations: Relevance in Breast Cancer & Potential Therapeutic Implications now - https://bit.ly/ESR1_ONCO_IQ_FB

This peer-reviewed ONCO-IQ quiz is designed for oncology professionals—a fast, high-yield knowledge check you can complete in minutes.

✅️ Understand how ESR1 ligand-binding domain mutations drive endocrine resistance
✅️ Interpret clinical prevalence and impact on treatment outcomes in ER+/HER2– advanced breast cancer
✅️ Apply genomic insights to real-world therapeutic decision-making

31/03/2026

🚨 Latest Update!

🔷 Real-world evidence generated using Guardant Health’s InfinityAI platform supported the approval of ENHERTU® (Trastuzumab deruxtecan) in Japan for previously treated HER2-positive advanced solid tumors, complementing data from DESTINY clinical trials.

🔷 This highlights the growing role of real-world evidence in precision oncology, enabling broader application of HER2-directed therapy across tumor types and informing regulatory decisions in biomarker-defined populations.

🔗 Read more: https://bit.ly/ONCOnews-31-Mar-01

31/03/2026

🔍Access the Steroid Equivalence Converter in ONCOassist®

Determining the equivalent dose of a different steroid.

Download the ONCOassist app:

📥 iOS: https://apple.co/4iuMxfS

📥 Android: https://bit.ly/oncoassistonandroid

📥Webapp: https://bit.ly/ONCOassistOnWeb

30/03/2026

🚨 Latest Update!

🔷 The EMA has recommended marketing authorisation for Imdylltra (Tarlatamab) as a monotherapy for adults with relapsed extensive-stage small cell lung cancer (ES-SCLC) after platinum-based chemotherapy, a setting with historically limited options. Backed by phase 3 data showing a median OS of 13.6 vs 8.3 months over standard of care, this represents a 40% reduction in risk of death.

🔷 Tarlatamab offers a novel treatment approach for patients with limited options in the relapsed ES-SCLC setting. The positive opinion highlights continued progress in expanding targeted therapies for aggressive lung cancers.

🔗 Read more: https://bit.ly/ONCOnews-30-Mar-01

27/03/2026

🔍Explore the NCCN Optimised Search on ONCOassist®

Access NCCN-based treatment guidance in ONCOassist, now enhanced with an advanced, clinician-led search built on key clinical inputs by our medical team. Currently covering 10 cancers, including colon, breast, and prostate, and expanding, it enables quicker, guideline-aligned decisions at the point of care.

Download the ONCOassist® app:

📥 iOS: https://apple.co/4iuMxfS

📥 Android: https://bit.ly/oncoassistonandroid

📥Webapp: https://bit.ly/ONCOassistOnWeb

27/03/2026

🚨 Latest Update!

🔷 The FDA has approved PD-L1 IHC 22C3 pharmDx as a companion diagnostic for patients with esophageal and gastroesophageal junction (GEJ) carcinoma, enabling identification of patients with PD-L1 CPS ≥1 who may benefit from pembrolizumab.

🔷 The approval strengthens precision oncology by supporting more personalized treatment decisions in upper gastrointestinal cancers. PD-L1 testing remains a key tool in optimizing therapy selection and improving clinical outcomes.

🔗 Read more: https://bit.ly/ONCOnews-23-Mar-03

27/03/2026

🚨 Latest Update!

🔷 The FDA has approved Lifyorli™ (Relacorilant) in combination with Nab-paclitaxel for patients with platinum-resistant ovarian cancer, introducing a novel treatment option in a difficult-to-treat setting.

🔷 Approval was based on the Phase 3 ROSELLA trial, where the combination improved overall survival (16.0 vs 11.9 months; HR 0.65) and progression-free survival (HR 0.70) versus chemotherapy alone.

🔷 Relacorilant, a selective glucocorticoid receptor antagonist, enhances chemotherapy activity through cortisol pathway modulation, offering a promising new approach for patients with limited therapeutic alternatives.

🔗 Read more: https://bit.ly/ONCOnews-27Mar-01